Pharma R&D Outsourcing Market Partnership Models & Emerging Destinations Reviewed in New Research Report

DALLAS, September 4, 2012 /PRNewswire/ --

ReportsnReports.com adds new a market research report "Partnership Models and Emerging Destinations for R&D Outsourcing" to its store. As outsourcing penetration has increased, pharma companies increasingly compete on how efficiently they interact with CROs. Strategic partnerships arose, in part, as a way to reduce the burden of oversight and costs of contracting. The report reviews how leading players are using strategic outsourcing to conduct drug development.

Features and benefits

• The report reviews how leading players are using strategic outsourcing to conduct drug development.
• The scope includes companies providing preclinical and clinical outsourced development services.

Highlights

CROs increasingly position themselves as strategic partners in drug development. Meanwhile, pharma companies are reducing the number of providers they partner with. Tactical outsourcing often brings a cost focus that can lead to compromises on quality; by contrast, strategic outsourcing aligns sponsor and CRO objectives.

Risk-sharing implies that the sponsor defrays the risk of delays and poor recruitment by incentivizing the CRO with bonus or penalty payments linked to key clinical trial metrics. Alternatively the CRO may agree to receive a percentage of future royalties as part payment, thereby offsetting the sponsor's risk of product failure.

Your key questions answered

• Gain insight into how to most efficiently collaborate with CROs.
• Understand the merits and drawbacks of outsourcing to emerging markets.

Buy your copy of this report @ http://www.reportsnreports.com/reports/190683-partnership-models-and-emerging-destinations-for-rd-outsourcing.html.

Table of Contents for the report Partnership Models and Emerging Destinations for R&D Outsourcing includes:

About This Report
Overview
Strategic scoping and focus
Contributors
Data sources and methodology
Methodology
Key findings
CROs are increasingly taking on the risks of drug development
From transactional to integrated: outsourcing relationships proceed through a series of stages
Clinical trials activity moving to emerging markets
China, Brazil, and India lead the growth in clinical trials
Emerging R&D locations will see the greatest investment and growth
Jordan, Egypt, and Qatar will lead the growth in R&D in the Middle East
Pfizer favors the functional service provider model

R&D Outsourcing Models
Introduction
Strategic models by degree of integration
Transactional (project-by-project) approach
Preferred provider
Partnership
Strategic alliance (risk-sharing)
Full integration
Service provision
Full-service outsourcing
Functional service providers
Niche outsourcing
Relationship management
Managing successful relationships
Exit strategies

Emerging Outsourcing Destinations
Introduction
Advantages of offshoring R&D activities
Preferred offshore R&D activities
Asia Pacific
India
China
Brazil
Russia
Eastern Europe
Poland
Czech Republic
Emerging destinations
Cuba
South Korea
Thailand
Bulgaria
Ukraine
Jordan
Argentina
Egypt
Qatar
Taiwan

Case Studies
Introduction
Pfizer: FSP model
Pfizer: FSP model (second iteration)
Pfizer: alliance partner model
Health Decisions: risk-sharing model
Covance: drug development partnership
Chorus (Eli Lilly): a fully outsourced model
BioStorage Technologies: a niche market

Appendix
Scope
Methodology
Glossary/abbreviations
Bibliography/references
Disclaimer

List of Tables
Table: Features and characteristics of outsourcing models
Table: Outsourcing experience across the spectrum of product development
Table: Characteristics of a successful outsourcing experience
Table: Comparison of traditional, tactical outsourcing model versus strategic model
Table: Features and characteristics of outsourcing models
Table: Characteristics of a strategic partnership
Table: Advantages and disadvantages to a sponsor of full-service outsourcing
Table: Benefits of an FSP relationship for the sponsor company
Table: Potential future opportunities for small CROs
Table: Factors contributing to the success of a CRO partnership
Table: Advantages and disadvantages of conducting clinical trials in China

List of Figures
Figure: Benefits of strategic outsourcing to client and CRO
Figure: Global patient enrollment, 2000 vs 2006
Figure: Growth in clinical trials in recently emerged regions, 2007-08 to 2009-10
Figure: Benefits of strategic outsourcing to client and CRO
Figure: Outsourcing models in order of increasing integration
Figure: The importance of size in pharma-CRO relationships
Figure: Comparison of FSP and full-service models
Figure: Clinical investigation forms filed in major world regions, 1997-2007
Figure: Global patient enrollment, 2000 vs. 2006
Figure: Emerging patient pools of "Western-type" diseases
Figure: Top candidates for offshore work
Figure: Annual number of investigative sites per million population, 2006-10
Figure: Growth in clinical trials in recently emerged regions, 2007-08 to 2009-10
Figure: Current pharmaceutical R&D capability in India
Figure: Current pharmaceutical R&D capability in China

Explore More Reports on the Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/.

Find newly published market research reports for other industries @ http://www.reportsnreports.com/latest-market-research.aspx.

About Us:

ReportsnReports.com (http://www.reportsnreports.com/) is an online market research reports library of 200,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Contact:
Priyank Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected]
Explore Company Profiles, SWOT Analysis Reports, Micro Markets & Country specific reports @ http://www.marketreportsonline.com/.

SOURCE ReportsnReports